Clinical Trial Update: Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial investigating intravenously administered recombinant vaccinia virus for metastatic, refractory colorectal carcinoma has completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Carcinoma

Drugs mentioned

• Recombinant Vaccinia Virus

Snippet

Sponsor: Jennerex Biotherapeutics | Conditions: Colorectal Carcinoma, CRC | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-01-08